JPMorgan Chase & Co. Acquires 129,335 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

JPMorgan Chase & Co. boosted its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 1,969.2% during the 3rd quarter, Holdings Channel.com reports. The fund owned 135,903 shares of the company’s stock after purchasing an additional 129,335 shares during the quarter. JPMorgan Chase & Co.’s holdings in Centessa Pharmaceuticals were worth $2,173,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CNTA. First Light Asset Management LLC increased its stake in Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after buying an additional 1,778,515 shares during the last quarter. Farallon Capital Management LLC increased its stake in Centessa Pharmaceuticals by 438.0% in the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after buying an additional 1,625,000 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at about $20,698,000. Franklin Resources Inc. increased its stake in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after buying an additional 1,145,823 shares during the last quarter. Finally, Driehaus Capital Management LLC increased its stake in Centessa Pharmaceuticals by 89.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after buying an additional 987,997 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Trading Up 8.6 %

Shares of CNTA stock opened at $16.46 on Wednesday. The company has a 50 day moving average of $16.83 and a 200-day moving average of $14.77. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 12-month low of $7.38 and a 12-month high of $18.97. The firm has a market cap of $2.17 billion, a P/E ratio of -10.76 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. Sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of the firm’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $15.38, for a total value of $180,591.96. Following the completion of the transaction, the insider now directly owns 183,266 shares of the company’s stock, valued at $2,818,631.08. This trade represents a 6.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Karen M. Anderson sold 5,876 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $17.01, for a total transaction of $99,950.76. Following the completion of the transaction, the insider now directly owns 71,525 shares of the company’s stock, valued at approximately $1,216,640.25. The trade was a 7.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 349,226 shares of company stock worth $6,036,765. Corporate insiders own 11.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on CNTA. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim raised their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.